Abstracts tagged "cytokines"

Abstract Number: 1824 • 2013 ACR/ARHP Annual Meeting
ONO-4059 – A Novel Small Molecule Dual Inhibitor Of Bruton’s Tyrosine Kinase (Btk) and Tec Kinase- Suppresses Osteoclastic Bone Resorption and Inflammation
Yuko Ariza¹, Toshio Yoshizawa¹, Yoshiko Ueda¹, Shingo Hotta¹, Tomoko Yasuhiro¹, Masami Narita¹, Yutaka Shichino² and Kazuhito Kawabata¹, ¹Discovery Research Laboratories 3, Ono Pharmaceutical Co., Ltd., Osaka, Japan, ²Discovery Research Laboratories, Ono Pharmaceutical Co., Ltd., Osaka, Japan
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by leukocyte infiltration, synoviocyte hyperplasia and osteoclastogenesis, leading to erosion of the joints and cartilage,…
Abstract Number: 941 • 2013 ACR/ARHP Annual Meeting
Mir-34a In Rheumatoid Arthritis: Characterisation Of Elevated Synovial Expression and Association With Treatment Resistance
Clare E Tange¹, Stefano Alivernini², Derek S. Gilchrist³, Lynn Crawford³, Ashleigh-Ann Rainey¹, Derek Baxter³, Iain B. Mcinnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ⁴Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Cells of the monocyte/macrophage lineage are critical to RA pathogenesis: unravelling mechanisms underlying macrophage inflammatory gene expression should elucidate novel disease-associated pathways and thereby…
Abstract Number: 2657 • 2013 ACR/ARHP Annual Meeting
Interactions Between Cigarette Smoking, Body Mass Index and Inflammatory Cytokine Levels In Determining The Risk Of Developing Rheumatoid Arthritis
Elizabeth V. Arkema¹, Susan Malspeis², Bing Lu³, Linda T. Hiraki⁴, Elizabeth W. Karlson² and Karen H. Costenbader², ¹Epidemiology, Harvard School of Public Health, Boston, MA, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ³Rheumatology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard School of Public Health, Boston, MA
Background/Purpose: Smoking and high body mass index (BMI) are risk factors for RA. Both are associated with increased systemic inflammation, with elevated C-reactive protein, interleukin…
Abstract Number: 1763 • 2013 ACR/ARHP Annual Meeting
IL4-10 Synerkine: A Novel Immunoregulatory Drug To Prevent Immunopathology In Rheumatic Diseases
Sarita Hartgring¹, Cristine Steen-louws², C.E. Hack³, Martin De Smet⁴, Floris Lafeber⁵ and J.A.G. van Roon⁶, ¹Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ²Rheumatology & Clinical Immunology/Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ³Immunology, UMC Utrecht, Utrecht, Netherlands, ⁴Lab Translational Immunology, UMC Utrecht, Utrecht, Netherlands, ⁵Rheumatology & Clinical Immunology, UMC Utrecht, Utrecht, Netherlands, ⁶Rheumatology & Clinical Immunology/Lab Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands
Background/Purpose: A considerable percentage of patients shows a limited response to biologics targeting one specific inflammatory mediator, largely because of redundancy of these mediators. An…
Abstract Number: 944 • 2013 ACR/ARHP Annual Meeting
Mir-125a: A Novel Regulator Of IL-6 and TLR Driven Pathways In RA Pathogenesis
Ashleigh-Ann Rainey¹, Derek S. Gilchrist², Clare E Tange¹, Marina Frleta³, Lynn Crawford², Derek Baxter², Iain B. Mcinnes⁴ and Mariola Kurowska-Stolarska⁵, ¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom, ²Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, ³Institute of infection, immunity and inflammation, University of Glasgow, Glasgow, United Kingdom, ⁴University of Glasgow, Glasgow, United Kingdom, ⁵Institute of Infection,Immunity and Inflammation, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: Molecular mechanisms driving disease initiation and chronicity in RA are incompletely understood. There is increasing interest in the role played therein by microRNAs –…
Abstract Number: 2573 • 2013 ACR/ARHP Annual Meeting
The Role Of STAT-3 In The Development Of Pulmonary and Dermal Fibrosis
Mesias Pedroza¹, Sarah To¹, Anuh T. George¹, David J. Tweardy² and Sandeep K. Agarwal¹, ¹Medicine, Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine, Houston, TX, ²Medicine, Section of Infectious Diseases, Baylor College of Medicine, Houston, TX
Background/Purpose: Fibrosis is the accumulation of excessive extra-cellular matrix in tissues, leading to tissue damage. In systemic sclerosis, the trigger is postulated to be an…
Abstract Number: 1766 • 2013 ACR/ARHP Annual Meeting
Role Of IL33 In The Inflammation Of Takayasu Arteritis
David Saadoun¹, Marlène Garrido², Julien Gaudric³, Cloé Comarmond⁴, Michele Rosenzwacjg⁵ and Patrice Cacoub⁶, ¹Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²I3 laboratory, Pitié-Salpétrière, Paris, France, ³Department of Vascular surgery GHPS, Paris, France, ⁴Internal Medicine and Clinical Imunology, Referal Center for Autoimmune diseases, Internal Medicine and Clinical Imunology, Hôpital Pitié Salpétrière, Paris, France, ⁵Department of Immunology GHPS, Paris, France, ⁶Médecine Interne 2, Hopital Pitié-Salpétrière, Paris, France
Background/Purpose: Interleukin (IL)-33, a member of the IL-1 cytokine family, is a recently described novel activator of endothelial cells, which promotes adhesion molecules and proinflammatory…
Abstract Number: 881 • 2013 ACR/ARHP Annual Meeting
Time To Renal Flare and Renal Disease Activity Over a 1 Year Period Is associated With Urinary TWEAK Levels In Patients With Systemic Lupus Erythematosus
Nicolas Wisniacki¹, Chris Stebbins², Jadwiga Bienkowska³, Susan Gawlak², Donald Bennett⁴, Yuhong Xiang⁵, Andrea Dearth⁶, Linda C. Burkly⁷, Ann Ranger⁶, Carrie Wager⁵, Laurence S. Magder⁸ and Michelle Petri⁹, ¹Medical Research, Biogen Idec, Maidenhead, United Kingdom, ²Translational Medicine, Biogen Idec, Cambridge, MA, ³Translational Medicine, Biogen Idec Inc., Cambridge, MA, ⁴Biostatistics, Biogen idec, Cambridge, MA, ⁵Biostatistics, Biogen Idec, Cambridge, MA, ⁶Biogen Idec Inc, Cambridge, MA, ⁷Biogen Idec, Cambridge, MA, ⁸Department of Epidemiology and Public Health, University of Maryland, Baltimore, MD, ⁹Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF superfamily that signals through its distinct, highly inducible receptor, FGF-inducible molecule 14…
Abstract Number: 2523 • 2012 ACR/ARHP Annual Meeting
Periodontal Pathogens Directly Promote Autoimmune Experimental Arthritis by Inducing a Toll-Like Receptor 2 and Interleukin-1 Driven Th17 Response
Shahla Abdollahi-Roodsaz¹, Sabrina Garcia de Aquino², Marije I. Koenders³, Fons A. van de Loo⁴, Ger J. Pruijn⁵, Mario J. Avila Campos⁶, Fernando Q. Cunha⁷, Joni A. Cirelli² and Wim B. van den Berg¹, ¹Rheumatology Research and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Diagnosis and Oral Surgery, Periodontic Division, Araraquara Dental School, Sao Paolo, Brazil, ³Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ⁴Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁵Department of Biomolecular Chemistry, Radboud University, Nijmegen, Netherlands, ⁶Department of Microbiology, Institute of Biomedical Sciences—ICB/USP, Sao Paulo, Brazil, ⁷Department of Pharmacology, School of Medicine of Ribeirao Preto, Sao Paolo, Brazil
Background/Purpose: The periodontal pathogen Porphyromonas gingivalishas been associated with the pathogenesis of rheumatoid arthritis (RA) because of its ability to citrullinate mammalian proteins and to…
Abstract Number: 1810 • 2012 ACR/ARHP Annual Meeting
Identification and Characterization of Synthetic Small Molecule Macrocycle Antagonists of Human IL17A
David Livingston, Sethu Alexander, Julian Bond, Timothy Briggs, Andrew Fraley, Stephen Hale, Tanya Landsman, Richard Martinelli, Kelley Shortsleeves, Nick Terrett and Nathan Walsh, Ensemble Therapeutics, Cambridge, MA
Background/Purpose: : IL17A has been demonstrated to be a key pro-inflammatory cytokine in human rheumatoid arthritis and in several rodent models of arthritis. Synthetic macrocycles…
Abstract Number: 1187 • 2012 ACR/ARHP Annual Meeting
Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity in Anti-Citrullinated Protein Antibody Positive Rheumatoid Arthritis: Decreased Inflammation and Disease Improvement with Smoking Cessation?
Catriona Cramb¹, Jeremy Sokolove², Geoffrey M. Thiele³, Gail S. Kerr⁴, Grant W. Cannon⁵, Andreas M. Reimold⁶, Ted R. Mikuls⁷ and William H. Robinson⁸, ¹VA Palo Alto Heatlh Care System and Stanford University, Palo Alto, CA, ²Medicine, VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ³Int Med/Sec of Rheum/Immun, Univ of Nebraska Med Ctr, Omaha, NE, ⁴Rheumatology, Washington DC VAMC, Georgetown and Howard University, Washington, DC, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT, ⁶Rheumatology, Dallas VA and University of Texas Southwestern, Dallas, TX, ⁷Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁸Division of Immunology and Rheumatology, Stanford University School of Medicine, Stanford, CA
Background/Purpose: Smoking is a major risk factor for rheumatoid arthritis (RA) and has been associated with increased disease severity and lower rates disease remission. We…
Abstract Number: 413 • 2012 ACR/ARHP Annual Meeting
α(1,2)-Linked Fucosylated Cytokines Are Upregulated in Rheumatoid Arthritis
Takeo Isozaki¹, Jeffrey H. Ruth², M. Asif Amin¹, Phillip L. Campbell¹, Christine M. Ha² and Alisa E. Koch³, ¹Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, ²Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ³Internal Medicine - Rheumatology, University of Michigan Medical School, Ann Arbor, MI
Background/Purpose: Glycosylation is a common post-translational modification of proteins in eukaryotes. Fucosylated glycans are synthesized by fucosyltransferases (futs). We previously reported that sialyl Lewisx, synthesized…
Abstract Number: 2525 • 2012 ACR/ARHP Annual Meeting
Bruton’s Tyrosine Kinase Inhibition Suppresses Inflammatory Cytokine Production and Affects Gene Expression in Human Macrophages and RA Synovial Tissue Explants
Linda M. Hartkamp¹, Inge E. van Es¹, Jay S. Fine², Michael Smith², John Woods², Satwant Narula³, Julie DeMartino², Paul P. Tak⁴ and Kris A. Reedquist¹, ¹Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Inflammation Discovery, Hoffmann-La Roche, Nutley, NJ, ³Inflammatory Discovery, Hoffmann-La Roche, Nutley, NJ, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam and GlaxoSmithKline, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and progressive autoinflammatory disorder characterized by the infiltration of inflammatory cells, including B-cells, T-cells and macrophages, in the…
Abstract Number: 1787 • 2012 ACR/ARHP Annual Meeting
Evolution of the Cytokine and Chemokine Profile in Patients Receiving Oral Daily Vitamin D: Results From a Randomized Controlled Trial
Benjamin Terrier¹, Marlène Garrido² and Patrice Cacoub Sr.³, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²I3 laboratory, Pitié-Salpétrière, Paris, France, ³Department of Internal Medicine 2., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose: Immunomodulatory effects of vitamin D were recently described in vitro, notably the expansion of regulatory T cells able to suppress inflammatory responses and the…
Abstract Number: 1131 • 2012 ACR/ARHP Annual Meeting
Intraarticular Infliximab for Knee Osteoarthritis: High Baseline Levels of Synovial Cellularity and High MRI Cartilage Injury At the Lateral Tibial Plateau Predict Improvement in Total WOMAC Score
Jeremy R. Schue¹, Ossama Tawfik², Rebecca Bolce³, Donald D. Smith¹, Gary Hinson⁴, Jo A. Wick⁵ and Herbert B. Lindsley⁶, ¹Internal Medicine, Kansas University Med Ctr, Kansas City, KS, ²Pathology, Kansas University Med Ctr, Kansas City, KS, ³Crescendo Bioscience Inc., South San Francisco, CA, ⁴Radiology, Kansas University Med Ctr, Kansas City, KS, ⁵Biostatistics, Kansas University Med Ctr, Kansas City, KS, ⁶Medicine, Kansas University Med Ctr, Kansas City, KS
Background/Purpose: Synovial tissue from patients with OA often demonstrates inflammation. We hypothesized that a single intraarticular (IA) injection of an anti-TNF drug would decrease inflammatory…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.